Overview and Basis of Presentation - Additional Information (Details) $ / shares in Units, $ in Thousands		1 Months Ended			12 Months Ended
	Oct. 01, 2020	Sep. 30, 2020 USD ($) shares	Aug. 31, 2020 USD ($) shares	Jul. 31, 2020 USD ($) $ / shares shares	Dec. 31, 2020 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares	Aug. 20, 2020
Overview And Basis Of Presentation [Line Items]
Distribution, record date	Sep. 22, 2020
Stockholders' equity, reverse stock split		one-for-nine reverse stock split
Stockholders' equity, reverse stock split, ratio		0.111111111
Accumulated deficit					$ (57,993)	$ (77,594)
Common stock, par value | $ / shares				$ 0.01	$ 0.01	$ 0.01
Common stock, shares authorized | shares				150,000,000	150,000,000	150,000,000
Extinguishment of debt				$ 32,600
Impact from recapitalization transactions				$ 69,879	$ 69,879
Gain on extinguishment					2,691
Additional capital contribution, shares | shares		9,000		740,000
Capital contribution from PDL		$ 97		$ 8,000	$ 20,666
Financial Support, Capital Contributions
Overview And Basis Of Presentation [Line Items]
Additional capital contribution, shares | shares			747,000
Capital contribution from PDL			$ 29,000
Issuance of common stock			8,334
Stock issued during period, remaining cash contribution amount			$ 20,666
Common Stock
Overview And Basis Of Presentation [Line Items]
Impact from recapitalization transactions, Shares | shares					6,221,000
Fair value of debt				$ 67,188
Impact from recapitalization transactions					$ 62
Additional capital contribution, shares | shares					2,146,000
Issuance of common stock					$ 21
Series A Preferred Stock
Overview And Basis Of Presentation [Line Items]
Number of shares exchanged | shares				30,000
PDL BioPharma, Inc
Overview And Basis Of Presentation [Line Items]
Shares distribution ratio to PDL shareholders	7.5879%
Shares issued in exchange for extinguishment of Preferred stock | shares				3,415,000
PDL BioPharma, Inc | Common Stock
Overview And Basis Of Presentation [Line Items]
Common stock shares issued in exchange for extinguishment of debt | shares				2,806,000
Impact from recapitalization transactions, Shares | shares				6,221,000
PDL BioPharma, Inc | LENSAR
Overview And Basis Of Presentation [Line Items]
Percentage of common stock owned						81.50%
PDL BioPharma, Inc | PDLIH
Overview And Basis Of Presentation [Line Items]
Distribution of ownership interest in its wholly owned subsidiary							100.00%